FDA Advises Virtual Ban On Amgen, J&J Anemia Drugs

Law360, New York (March 13, 2008, 12:00 AM EDT) -- A U.S. Food and Drug Administration panel reportedly voted Thursday to ban the use of anemia drugs, including Amgen Inc.'s Aranesp and Epogen and Johnson & Johnson's Procrit, in most cancer patients.

The Oncologic Drugs Advisory Committee voted 9-5 that the drugs shouldn't be used at all in patients with breast cancer or head and neck cancer, according to Dow Jones.

The panel advised that the drugs, known as erythropoiesis-stimulating agents, should only be part of a treatment if the patient has advanced metastatic cancer or...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.